Abstract:12047 Background: Metastatic colorectal cancer (mCRC) is a leading cause of death, particularly in older adults. Regorafenib (REGO) is an FDA-approved oral multi-kinase inhibitor for refractory mCRC based on the CORRECT trial results, but older adults were underrepresented with a median age of 61 (54–67). This study aimed to evaluate REGO safety in older adults with mCRC and assess the feasibility of using geriatric assessment (GA) to predict toxicity risk. Methods: 27 subjects (PTs) enrolled (median age 73, range 65-85) and started at 120mg of REGO for 21 days of a 28-day cycle with provider discretion to escalate to full dose of 160mg after cycle 1. GA was conducted at enrollment, 4 weeks later, and then every 3 months to monitor for any deterioration. GA assessed 8 geriatric domains (comorbidity, functional status, physical performance, cognition, psychological state, nutrition, medication review, and social support) using validated tools. Primary objective was to assess grade 3-5 toxicity rate, with secondary objectives evaluating REGO efficacy and exploring baseline GA and toxicity risk associations. Kaplan-Meier method was used to estimate median overall survival (OS) and progression-free survival (PFS) from date of consent. Continuous GA measures were compared using non-parametric Wilcoxon rank-sum test, and binary GA measures were compared using Fisher’s exact test. Results: Of 27 PTs enrolled, 15 were male, 12 were female, and 19 identified as white. At baseline, 77.7% of PTs had at least 3 (1-9) GA impairments. Physical performance (80.8%), comorbidity (75%), and cognition (69.2%) were the most prevalent impaired GA domains. 40% required dose reduction by end of cycle 2, and none escalated to full dose. 55% of PTs completed cycle 3. Main reasons for drug discontinuation were disease progression (80%) and toxicity (12%). 74.1% of PTs experienced at least one treatment-related grade 3-4 toxicity. Fatigue (33%), hypertension (30%), and hand-foot syndrome (15%) were the leading grade 3-4 toxicities. Median OS was 5.6 months (95% CI: 3.6-12.2m), and median PFS was 2.8 months (95% CI: 2.5-3.4m). There was no significant difference in baseline GA measures between those who experienced toxicities and those who did not. No statistically significant toxicity risk was associated with any baseline GA impairment. The prevalence of impaired mini-nutritional assessment increased over 4 weeks (58% to 91%, p < 0.01), and median Short Physical Performance Battery (SPPB) scores decreased (7 to 6, p = 0.03). Conclusions: The study found that older adults with mCRC had comparable survival with REGO but experienced high toxicity. This may be ameliorated by recently published step-wise REDOS dosing method and should be considered in older adults with mCRC. The study confirms the feasibility of implementing GA within clinical trials. More data is needed on the role of GA in predicting toxicity with targeted therapies. Clinical trial information: NCT02466009 .

Real world (RW) use and outcomes of regorafenib (REG) flexible dosing in patients (pts) with metastatic colorectal cancer (mCRC) in Europe.

Real-world dosing of regorafenib and outcomes among patients with metastatic colorectal cancer: a retrospective analysis using US claims data

Real-world (RW) study in patients (pts) with metastatic colorectal cancer (mCRC) with long-term responses to regorafenib in the USA.

Real world effectiveness of regorafenib in heavily pretreated patients with metastatic colorectal cancer.

Treatment modalities of regorafenib and survival in metastatic colorectal (mCRC) patients: A real-world multicenter retrospective study.

Efficacy, treatment modalities, and safety of regorafenib in Chinese metastatic colorectal cancer patients: A multiple centers real-world study.

A multiple centers real-world study of regorafenib treatment modalities in Chinese metastatic colorectal cancer patients.

Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial.

Contemporary Real-World Evidence in Unresectable HCC (uhcc) Patients Treated with Regorafenib in Taiwan: Interim Results from the Observational REFINE Study.

Regorafenib plus PD-1 inhibitors in Chinese patients with microsatellite stable/mismatch repair proficient metastatic colorectal cancer: A real-world study.

Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence

433P A Phase Ib/II Clinical Trial of Tolerability, Safety and Efficacy of Regorafenib in Combination with Toripalimab (a PD-1 Antibody) in Patients with Relapsed or Metastatic Colorectal Cancer

Real-world biomarker testing patterns among patients with metastatic colorectal cancer (mCRC) treated with later lines of therapy (LOT) in the United States (US) community oncology setting.

Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).

Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study

Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study

Real-world clinical efficacy of epidermal growth factor receptor inhibitors (EGFRi) in patients with early-onset (eo), metastatic colorectal cancer (mCRC).

Efficacy and safety of regorafenib plus biweekly TAS-102 for refractory metastatic colorectal cancer (REGTAS): A multicenter single-arm phase II trial.

Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study

The Optimal First-Line Treatment for Patients with Left-Sided RAS Wild-Type Metastatic Colorectal Cancer: Double-drug Regimen or Triple-Drug Regimen Therapy

Neoadjuvant treatment with re gorafenib and cap ecitabine combined with radiotherapy in locally advanced rectal cancer: a multicenter phase Ib trial (RECAP)–SAKK 41/16